Quanterix earnings release, August 10, 2026

Quanterix Corp (QTRX) · Form 8-K, Item 2.02 · Filed · SEC filing

Quanterix Releases Financial Results for the Second Quarter of 2026

Reports $32.9 million in revenue and $96.9 million of cash and marketable securities

Company accelerating initiatives to drive commercial effectiveness

Revises financial outlook for 2026 and extends date for attaining cash-flow break-even

BILLERICA,

Mass. – August 10, 2026

-- Quanterix Corporation

(NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026.

“We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to improve commercial performance, including reorganizing our teams and adding seasoned leadership to sharpen accountability, accelerate execution, and improve operating results in the second half and beyond,” said Everett Cunningham, President & CEO of Quanterix. “We remain confident in the strength and differentiated positioning of both our research tools and diagnostics businesses, especially with enhanced commercial leadership and discipline enabling a renewed focus on returning to sustained growth. Our capabilities in ultra-sensitive protein-detection in blood and high plex spatial analysis in tissue, combined with a differentiated multi-analyte approach, position us well across targeted translational research and diagnostics. With strategic Diagnostics investments underway, our management team can now focus on achieving key milestones in Alzheimer’s disease testing, including completing three clinical utility studies and advancing our FDA roadmap.”

Second Quarter Financial Highlights

• Revenue of $32.9 million, an increase of 34% compared to $24.5 million in the prior year.

• GAAP gross margin of 38.5%, as compared to 40.9% in the prior year. Adjusted gross margin (non-GAAP) of 47.9% compared to 41.8% in the prior year. Prior year GAAP margins are updated to reflect a change in accounting policy in Q1’26 related to shipping and handling costs. Shipping and handling costs for product sales are now recorded in the cost of product revenue in the Company’s GAAP financials.

• Adjusted EBITDA (non-GAAP) loss of $10.0 million, compared to $13.7 million in the prior year.

• The Company ended the second quarter with $96.9 million of cash, cash equivalents, marketable securities, and restricted cash. Adjusted cash usage, after accounting for integration and certain employee separation costs of $1.7 million, was $4.0 million in the second quarter, a decrease in usage of $10.8 million from the first quarter of 2026.

• The Company completed its ERP system integration, the final step of the Akoya acquisition integration program that realized $85 million in savings on an annualized basis.

• Quanterix incurred a $26.9 million goodwill impairment related to the Akoya acquisition as required under GAAP accounting based on recent circumstances within the business. The adjustment does not impact operations or liquidity.

Operational and Business Highlights

• Quanterix finished building its senior management team ahead of its anticipated higher growth phase, especially in the Diagnostics business. Jim Gute was named Chief Commercial Officer, as announced separately today. Industry veteran Geoff Albrecht was appointed Senior Vice President and General Manager of Diagnostics, Anthony Catalano was named Chief Operating Officer and Jason Faessler was appointed Chief Financial Officer.

• Several milestones to advance clinical adoption of blood-based Alzheimer’s testing were announced, including commercial insurance coverage. Beginning July 1, 2026, members covered under Anthem Blue Cross and Blue Shield medical policies can receive coverage for qualifying blood-based biomarker testing, including Quanterix’s Lucent AD® Complete, when medical necessity criteria are met.

• A peer-reviewed study evaluating Lucent AD® Complete alongside an algorithmic immunoprecipitation mass spectrometry (IP-MS) approach on a shared patient cohort demonstrated the high diagnostic parity and three-fold reduced diagnostic ambiguity provided by Quanterix’s multi-analyte algorithmic blood testing approach.

• New clinical data presented at the Alzheimer’s Association International Conference (AAIC) 2026 highlighted how multi-biomarker testing improves detection of early Alzheimer's and provides a more comprehensive framework for guiding patient care.

• Quanterix was selected as a Co-Investigator institution in the PD-BUILD program, in the Aligning Science Across Parkinson’s Collaborative Research Network 2026 expansion, supported by The Michael J. Fox Foundation. This multi-year grant funds development and deployment of high-quality biomarker tools aimed at enabling earlier detection, improved patient stratification, and more effective monitoring of Parkinson’s disease in clinical research. Quanterix and its Simoa platform will develop and distribute validated single-plex and multiplex biomarker assays to Parkinson’s disease researchers globally.

• Quanterix launched Simoa® Ultra-Sensitive Immunoassay NPTX2, an important emerging synaptic biomarker.

• Two new spatial products were launched: Spatial Molecular Barcoding kit for the Phenocycler Fusion for early access and Spatial Spectral DAPI 2.0 for the Phenoimager HT.

2026 Business Outlook... (truncated)ash balance, compared to $100 million previously. The company expects to end the year with no debt.

Conference Call

In conjunction with this announcement, the Company will host a conference call today, August 10, 2026, at 8:30 AM ET. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 9896910.

Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.

About Quanterix

Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.

Financial statements

Income Statement

Three Months Ended June 30, — (unaudited, amounts in thousands, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenues:Product revenue23,47616,83248,95637,572
Revenues:Service and other revenue9,0187,11219,39415,935
Revenues:Collaboration and license revenue4125329721,303
Revenues:Total revenues32,90624,47669,32254,810
Costs of goods sold and services:Cost of product revenue14,62110,59429,76121,935
Costs of goods sold and services:Cost of service and other revenue5,6113,88111,3208,035
Costs of goods sold and services:Total costs of goods sold and services20,23214,47541,08129,970
Costs of goods sold and services:Gross profit12,67410,00128,24124,840
Operating expenses:Research and development7,8219,08115,14419,117
Operating expenses:Selling, general and administrative27,35030,35057,12161,520
Operating expenses:Impairment and restructuring costs26,9347,67046,7697,670
Operating expenses:Total operating expenses62,10547,101119,03488,307
Operating expenses:Loss from operations-49,431-37,100-90,793-63,467
Other income (expense), net:Interest income7612,6921,6535,962
Other income (expense), net:Change in fair value of contingent liabilities-794,2731,4223,894
Other income (expense), net:Other income (expense), net-2394921,182108
Other income (expense), net:Loss before income taxes-48,988-30,086-66,536-53,503
Other income (expense), net:Income tax benefit5473612,986
Other income (expense), net:Net loss-48,934-30,013-66,475-50,517
Other income (expense), net:Net loss per common share, basic and diluted-1.04-0.77-1.41-1.3
Other income (expense), net:Weighted-average common shares outstanding, basic and diluted47,16738,89347,06838,801

Income Statement

Three Months Ended June 30, — (unaudited, amounts in thousands, except percentages)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net loss-48,934-30,013-66,475-50,517
Interest income-761-2,692-1,653-5,962
Income tax benefit-54-73-61-2,986
Depreciation and amortization6,1341,99911,7374,187
Stock-based compensation expense (1)4,2125,3738,38810,834
Acquisition and integration related costs (2)8524,1392,0047,717
Earnout recorded as compensation expense (3)4,1567,900
Changes in contingent liabilities (4)79-4,273-1,422-3,894
Impairment and employee separation costs (5)28,4837,67049,2717,670
Income from contract termination (6)-21,596
Adjusted EBITDA (non-GAAP)-9,989-13,714-19,807-25,051
Total revenues32,90624,47669,32254,810
Adjusted EBITDA margin (non-GAAP) (adjusted EBITDA as a % of revenue)-30.4-56-28.6-45.7%

Income Statement

Three Months Ended June 30, — (unaudited, amounts in thousands, except percentages)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Gross profit12,67410,00128,24124,840
Purchase accounting impact on inventory and property and equipment (1)203402
Amortization of acquired intangible assets (2)2,8862345,658461
Adjusted gross profit (non-GAAP)15,76310,23534,30125,301
Total revenues32,90624,47669,32254,810
Gross margin (gross profit as % of total revenues)38.5%40.9%40.7%45.3%
Adjusted gross margin (non-GAAP) (adjusted gross profit as % of total revenues)47.9%41.8%49.5%46.2%
Total operating expenses62,10547,101119,03488,307
Purchase accounting impact on property and equipment (1)-969-1,192
Amortization of acquired intangible assets (2)-50-127
Acquisition and integration related costs (3)-852-4,139-2,004-7,717
Earnout recorded as compensation expense (4)-4,156-7,900
Impairment and employee separation costs (5)-28,484-7,670-49,270-7,670
Adjusted total operating expenses (non-GAAP)31,75031,13666,44165,020
Loss from operations-49,431-37,100-90,793-63,467
Purchase accounting impact on inventory and property and equipment (1)1,1721,594
Amortization of acquired intangible assets (2)2,9362345,785461
Acquisition and integration related costs (3)8524,1392,0047,717
Earnout recorded as compensation expense (4)4,1567,900
Impairment and employee separation costs (5)28,4847,67049,2707,670
Adjusted loss from operations (non-GAAP)-15,987-20,901-32,140-39,719

Balance Sheet

June 30, 2026 — (unaudited, amounts in thousands, except per share data)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents44,16929,839
Current assets:Marketable securities49,36088,393
Current assets:Accounts receivable, net of allowance for expected credit losses22,34529,972
Current assets:Inventory47,60154,763
Current assets:Prepaid expenses and other current assets7,5769,290
Current assets:Total current assets171,051212,257
Current assets:Restricted cash3,3483,341
Current assets:Property and equipment, net20,00223,672
Current assets:Intangible assets, net105,782131,787
Current assets:Goodwill26,376
Current assets:Operating lease right-of-use assets15,05316,664
Current assets:Other non-current assets4,3914,669
Current assets:Total assets319,627418,766

Cash Flow

Six Months Ended June 30, — (unaudited, amounts in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net loss-66,475-50,517
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization expense11,7374,187
Adjustments to reconcile net loss to net cash used in operating activities:Credit losses on accounts receivable516-262
Adjustments to reconcile net loss to net cash used in operating activities:Accretion of marketable securities-202-1,567
Adjustments to reconcile net loss to net cash used in operating activities:Operating lease right-of-use asset amortization1,601850
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense8,73910,834
Adjustments to reconcile net loss to net cash used in operating activities:Impairment46,7696,374
Adjustments to reconcile net loss to net cash used in operating activities:Change in fair value of contingent liabilities-1,422-3,894
Adjustments to reconcile net loss to net cash used in operating activities:Recognition of off-market liability-13,975
Adjustments to reconcile net loss to net cash used in operating activities:Other operating activity-558-370
Changes in assets and liabilities:Accounts receivable6,8179,476
Changes in assets and liabilities:Inventory7,6522,993
Changes in assets and liabilities:Prepaid expenses and other current assets1,5611,942
Changes in assets and liabilities:Accounts payable-6,7632,796
Changes in assets and liabilities:Accrued compensation and benefits, accrued expenses, and other current liabilities-6,3771,605
Changes in assets and liabilities:Deferred revenue-9,163583
Changes in assets and liabilities:Net change in other operating assets and liabilities-3,683-4,573
Changes in assets and liabilities:Net cash used in operating activities-23,226-19,543
Cash flows from investing activities:Purchases of marketable securities-8,245-30,245
Cash flows from investing activities:Proceeds from sales and maturities of marketable securities47,354135,874
Cash flows from investing activities:Purchases of property and equipment-183-2,033
Cash flows from investing activities:Acquisitions, net of cash acquired-8,954
Cash flows from investing activities:Net cash provided by investing activities38,92694,642
Cash flows from financing activities:Deferred acquisition payments-1,439
Cash flows from financing activities:Principal payments on financing leases-171
Cash flows from financing activities:Proceeds from common stock issued under stock plans340668
Cash flows from financing activities:Payments for employee taxes withheld on stock-based compensation awards-27-1,004
Cash flows from financing activities:Net cash used in financing activities-1,297-336
Cash flows from financing activities:Net increase in cash, cash equivalents, and restricted cash14,40374,763
Cash flows from financing activities:Effect of exchange rate changes on cash, cash equivalents, and restricted cash-661,455
Cash flows from financing activities:Cash, cash equivalents, and restricted cash at beginning of period33,18059,319
Cash flows from financing activities:Cash, cash equivalents, and restricted cash at end of period47,517135,537
Full release

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements about Quanterix’s future business outlook, operations, strategy and financial performance, including statements related to our expectations about consistent profitable revenue growth and achieving cash flow breakeven performance, the development and commercialization of our products, and under the header “2026 Business Outlook.”. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities with respect to Quanterix’s future business, operations, strategy and financial performance: risks related to the impact of changes in U.S. government policies, including impacts of tariffs and reductions in federal research funding; risks associated with the anticipated timing for launch of, and features of, Quanterix’s next-generation instruments to upgrade its existing platforms; risks related to Quanterix’s ability to improve existing diagnostics and develop new diagnostic tests and tools; risks related to Quanterix’s ability to successfully penetrate the diagnostics market; risks related to Quanterix’s ability to retain and expand its customer base and achieve sufficient market acceptance of its products; risks related to the ability of Quanterix’s contract manufacturers and suppliers to reliably and consistently manufacture and supply our instruments; risks that Quanterix may fail to realize the anticipated benefits from its recent acquisitions of Emission, Inc. and Akoya Biosciences, Inc.; risks that Quanterix’s estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect; risks related to Quanterix’s ability to maintain effective internal control over financial reporting and disclosure controls and procedures; and risks related to defects or other quality issues in Quanterix’s products that could lead to unforeseen costs, product recalls, adverse regulatory actions, negative publicity and litigation. Additional factors that could cause results to differ materially from those described above can be found in the periodic reports filed by Quanterix with the SEC, including the “Risk Factors” sections contained therein, which are available on the SEC’s website at www.sec.gov.

All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.

FINANCIAL HIGHLIGHTS

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Quanterix earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.